The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Eloqua, Inc. in Connection with the Sale of the Company to Oracle Corporation

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky is investigating the Board of Directors of Eloqua, Inc. (“Eloqua” or the “Company”) ELOQ for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Oracle Corporation ORCL.

Click here to learn how to join the action: http://zlk.9nl.com/eloqua-eloq/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, Eloqua shareholders will receive $23.50 for each share of Eloqua stock they own. The investigation concerns whether the Eloqua Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before entering into this transaction and whether Oracle Corporation is underpaying for Eloqua shares, thus unlawfully harming Eloqua stockholders. In particular, at least one analyst set a price target of $27.00 per Eloqua share.

If you own common stock in Eloqua and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or http://zlk.9nl.com/eloqua-eloq/.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.